Moreover, its role in predicting a potential treatment response in T2DM patients at higher risk of HFpEF remains unclear, while NT-proBNP remains an effective tool for eligibility and enrichment for CV events mainly in established HF. The gene discussed is NPPB; the disease is type 2 diabetes mellitus.